News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
55
Sources here
12
Companies here
1
Search results Stored financial headlines

Active search

55 matching headlines

Ticker or company: NRIXMain company stories
Clear
Latest

MarketBeat Earnings

Handelsbanken Fonder AB Buys 86,000 Shares of Nurix Therapeutics, Inc. $NRIX

Handelsbanken Fonder AB increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 15.7% in the second quarter, acquiring an additional 86,000 shares, bringing its total holdings to 633,000 shares valued at approximately $15.4 million. Despite this institutional buying, insiders sold a significant number of shares, and Nurix reported quarterly earnings and revenue below analyst expectations. Analyst sentiment remains "Moderate …

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Simply Wall Street Earnings Main company 🇺🇸 United States

Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche

Nurix Therapeutics received a US$10 million milestone payment from Sanofi for advancing an oral STAT6 degrader into a Phase 1 trial and initiated a global Phase 3 study with Roche for its BTK degrader bexobrutideg. These developments highlight the progression of Nurix's DEL-AI platform …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Earnings Main company 🇺🇸 United States

Nurix Therapeutics stock hits 52-week high at $26.40 By Investing.com

Nurix Therapeutics (NRIX) stock has reached a 52-week high of $26.40, marking a 1-year return of 159%, and is currently trading near its Fair Value with a market capitalization of $2.72 billion. Analysts predict the company will achieve profitability this year with an expected …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com Earnings Main company 🇺🇸 United States

Nurix Therapeutics stock hits 52-week high at $26.40

Nurix Therapeutics Inc. (NRIX) stock has reached a new 52-week high of $26.40, marking a 159% return over the past year. Analysts expect the company to be profitable this year, with EPS projected at $3.80, and major firms like Mizuho, Truist Securities, Baird, and …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Renaissance Technologies LLC Invests $1.83 Million in Nurix Therapeutics, Inc. $NRIX

Renaissance Technologies LLC recently acquired a new position in Nurix Therapeutics, Inc. worth approximately $1.83 million during the first quarter. Despite this institutional investment and a "Moderate Buy" consensus rating from analysts, Nurix Therapeutics reported weaker-than-expected quarterly results, including an EPS loss of $0.81 …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Sei Investments Co. Buys 46,132 Shares of Nurix Therapeutics, Inc. $NRIX

Sei Investments Co. significantly increased its stake in Nurix Therapeutics (NASDAQ:NRIX) during the first quarter, purchasing an additional 46,132 shares and bringing its total holdings to 82,108 shares valued at $1.27 million. Despite recent weaker-than-expected quarterly earnings and insider share sales, analysts largely maintain …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade

Nurix Therapeutics (NASDAQ:NRIX) reached a new 52-week high after Royal Bank of Canada raised its price target from $33 to $36, maintaining an "outperform" rating. Despite positive analyst sentiment with a "Moderate Buy" consensus, the company continues to report financial losses, missing revenue and …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Royal Bank Of Canada Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00

Royal Bank of Canada increased its price target for Nurix Therapeutics (NASDAQ:NRIX) from $33.00 to $36.00, maintaining an "outperform" rating, indicating a potential 40.7% upside. This adjustment comes despite the company missing quarterly earnings and revenue estimates, and notable insider selling. Overall analyst sentiment …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Analyst action Main company 🇺🇸 United States

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Earnings Main company 🇺🇸 United States

Why Nurix Therapeutics (NRIX) Is Back In The Spotlight

Nurix Therapeutics (NRIX) is gaining investor attention following the enrollment of the first patient in its Phase 3 DAYBreak CLL-306 trial for bexobrutideg and a $10 million milestone payment from Sanofi. The company has seen significant share price appreciation over the past year, although …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Dimensional Fund Advisors LP Purchases 349,710 Shares of Nurix Therapeutics, Inc. $NRIX

Dimensional Fund Advisors LP significantly increased its stake in Nurix Therapeutics, Inc. by 81.1%, purchasing an additional 349,710 shares to hold a total of 780,696 shares valued at $12.1 million. This comes despite Nurix Therapeutics reporting weaker-than-expected quarterly results, including a wider loss per …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of "Moderate Buy" by Brokerages

Nurix Therapeutics (NASDAQ:NRIX) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month price target of $34.00, significantly above its current trading price of $25.53. Several analysts, including those from Stifel, HC Wainwright, BTIG Research, Royal Bank Of Canada, and …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Nurix Therapeutics (NASDAQ:NRIX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded Nurix Therapeutics (NASDAQ:NRIX) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $34.00. The company's shares opened at $25.53, nearing their 52-week high, and have shown …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 4,356 Shares of Stock

Nurix Therapeutics insider Gwenn Hansen sold 4,356 shares of NRIX stock for $108,900 at $25 per share, reducing her ownership by 3.58%. This transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving her with 117,227 shares. Despite a quarterly loss and missed revenue estimates, …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Market update Main company 🇺🇸 United States

How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche

Nurix Therapeutics has reached two significant milestones: a $10 million payment from Sanofi for a STAT6 degrader trial and the enrollment of the first patient in a global Phase 3 study of bexobrutideg with Roche. These advancements underscore Nurix's DEL-AI discovery platform and partnering …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins

Nurix Therapeutics (NRIX) has announced a $10 million milestone payment from Sanofi for the first-in-human trial of an oral STAT6 degrader and the enrollment of the first patient in a pivotal Phase 3 trial for bexobrutideg with Roche. These developments highlight Nurix's progress in …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High - Still a Buy?

Nurix Therapeutics (NASDAQ:NRIX) recently hit a new 52-week high of $25.40 after announcing a $10 million milestone payment from Sanofi and the initiation of a Phase 3 trial for bexobrutideg. Despite positive analyst sentiment, with a consensus "Moderate Buy" rating and a $34 price …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Canada Earnings Main company 🇺🇸 United States

Nurix Therapeutics stock hits 52-week high at $25.22 By Investing.com

Nurix Therapeutics (NRIX) stock has reached a 52-week high, closing at $25.22, signifying a 140.54% increase over the past year. This performance, including a 118% total return, is supported by strong investor confidence and recent positive analyst updates following the company's Q2 2026 earnings …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Houte Hans Van Sells 4,761 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics CFO Houte Hans Van sold 4,761 shares of the company's stock for approximately $116,000, reducing his ownership by 10.6% to 40,166 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. The company's shares opened at $24.69, near their 52-week …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Nurix Therapeutics (NRIX) insider plans $385K sale of stock options and RSUs

Nurix Therapeutics (NRIX) insider Christine Ring has filed to sell up to 16,589 common shares, valued at approximately $385,030.69, through Morgan Stanley Smith Barney LLC. The shares originate from stock option exercises and restricted stock units. This filing also references previous Rule 10b5-1 sales, …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 4 Nurix Therapeutics Inc For: 4 August By Investing.com

This article from Investing.com is a simple, brief notice about a Form 4 filing for Nurix Therapeutics Inc. The filing was made for August 4th, 2026. The article itself contains no further details about the content of the Form 4.

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Earnings Main company 🇺🇸 United States

NRIX Looks 273.5% Overvalued on GF Value™

Nurix Therapeutics Inc (NRIX) has received a $10 million milestone payment from Sanofi for a Phase 1 clinical trial, highlighting pipeline progress. Despite this, the company appears significantly overvalued, with a Price-to-Sales ratio of 63.44 and a GF Value indicating it is 273.5% overvalued. …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
marketscreener.com Earnings Main company 🇺🇸 United States

Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader

Nurix Therapeutics received a $10 million milestone payment from Sanofi as Sanofi initiated a Phase 1 clinical trial for a STAT6 degrader. This payment reflects progress in their collaboration. Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC has reiterated its "buy" rating for Nurix Therapeutics (NASDAQ:NRIX), setting a price target of $34.00, suggesting a potential upside of over 40%. This comes despite Nurix reporting weaker-than-expected quarterly results with an EPS loss of $0.81 and revenue of $9.04 …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics, Inc. announced it has received a $10 million milestone payment from Sanofi following the initiation of a Phase 1 clinical trial for SAR448272/NX-3911, an oral STAT6 degrader for type 2 inflammatory diseases. This payment brings the total received by Nurix under its …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Nurix Therapeutics chief legal officer Christine Ring sells $382k stock

Christine Ring, Nurix Therapeutics' Chief Legal Officer, sold 16,589 shares worth $382,358 on August 3, 2026, while also acquiring 5,787 shares through stock options for $50,462. These transactions, executed under a Rule 10b5-1 plan, leave her with 9,110 direct shares and 122,824 employee stock …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Nurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care

Nurix Therapeutics has enrolled the first patient in its global Phase 3 DAYBreak CLL-306 trial for bexobrutideg, a potential best-in-class BTK degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This registrational study, conducted in collaboration with Roche, compares bexobrutideg against pirtobrutinib, …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Perceptive Advisors LLC Has $57.52 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX

Perceptive Advisors LLC increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 4.4% in the first quarter, now owning 3.71 million shares valued at $57.52 million, representing 3.59% of the company. Despite Nurix missing Q1 analyst estimates for earnings and revenue, Wall Street analysts maintain …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Houte Hans Van Sells 2,845 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics CFO Houte Hans Van sold 2,845 shares of the company's stock for $66,516.10 to cover tax withholding on vested equity awards, reducing his direct holdings by 5.96%. NRIX shares traded near their 52-week high, despite the company reporting quarterly earnings and revenue …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,847 Shares of Stock

Nurix Therapeutics insider Gwenn Hansen recently sold 3,847 shares of NRIX stock for $23.38 per share, totaling $89,942.86. This sale was primarily to cover tax withholding obligations from vested equity awards. Despite missing recent earnings and revenue estimates, analysts generally maintain a "Moderate Buy" …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

The Technical Signals Behind (NRIX) That Institutions Follow

An analysis of Nurix Therapeutics Inc. (NASDAQ: NRIX) reveals neutral near and mid-term readings but a positive long-term bias. The article highlights a mid-channel oscillation pattern and a significant 64.5:1 risk-reward setup, targeting an 18.3% gain against 0.3% risk. It also outlines specific AI-generated …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Vanguard Capital Management (NRIX) discloses 5.03% Nurix Therapeutics ownership stake

Vanguard Capital Management LLC and its affiliates have disclosed a beneficial ownership stake of 5.03% in Nurix Therapeutics Inc. (NRIX), as per a Schedule 13G SEC filing. This amounts to 5,202,025 shares of common stock as of June 30, 2026. Vanguard holds sole voting …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 4 Nurix Therapeutics Inc For: 30 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Nurix Therapeutics Inc., pertaining to transactions made on July 30. The brief update includes the stock symbol NRIX and indicates a slight price change of -1.57%.

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Nurix therapeutics CFO Hans van Houte sells $66,524 in shares

Nurix Therapeutics CFO Hans van Houte sold 2,845 shares to cover tax withholding obligations from restricted stock unit vesting, totaling approximately $66,524. This transaction occurred as the stock trades near its 52-week high and has seen a 98% gain over the past year. Concurrently, …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Nurix therapeutics CSO Gwenn Hansen sells $89,953 in stock

Gwenn Hansen, CSO of Nurix Therapeutics, sold 3,847 shares of common stock for $89,953 to cover tax obligations from restricted stock unit vesting. This transaction occurred as NRIX stock reached near its 52-week high, with the company also recently acquiring 10,180 shares through RSU …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Stempoint Capital LP Makes New $4.89 Million Investment in Nurix Therapeutics, Inc. $NRIX

Stempoint Capital LP has made a new $4.89 million investment in Nurix Therapeutics, acquiring 315,226 shares, representing a 0.30% stake. This comes amidst mixed news for Nurix, with other institutional investors increasing positions and analysts maintaining a "Moderate Buy" consensus despite the company missing …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context